New PubCo directors and majority stake outlined in Horizon Space (HSPT) merger update

Rhea-AI Filing Summary

Horizon Space Acquisition II Corp. filed additional proxy solicitation materials related to its proposed business combination with SL BIO Ltd., mainly updating governance and ownership details for the future combined company, SL Science Holding Limited (PubCo).

The filing adds two independent director nominees for PubCo, Joseph Levinson and Qian (Hebe) Xu, and updates the post-closing beneficial ownership table. In the no-redemption scenario, PubCo is expected to have 566,591,350 ordinary shares outstanding, with William Wang beneficially owning 333,832,129 shares, representing 58.9% of PubCo’s voting power.

In the maximum redemption scenario, PubCo is expected to have 559,956,923 ordinary shares outstanding, with William Wang’s voting power at 59.6%. The meeting date, time, location, record date, and redemption deadline for the February 12, 2026 Business Combination Meeting remain unchanged.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 6, 2026

HORIZON SPACE ACQUISITION II CORP.

(Exact name of registrant as specified in its charter)

Cayman Islands		001-42406		N/A
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification Number)

1412 Broadway
21st Floor, Suite 21V
New York, NY 10018
(Address of principal executive offices)

Tel: (646) 257-5537
(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☒ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☒ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act.

Title of each class		Trading Symbol		Name of each exchange on which registered
Units, consisting of one ordinary share, $0.0001 par value, and one Right to acquire one-tenth of one ordinary share		HSPTU		The Nasdaq Stock Market LLC
Ordinary shares, par value $0.0001 per share		HSPT		The Nasdaq Stock Market LLC
Rights, each whole right to acquire one-tenth of one ordinary share		HSPTR		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

Additional Definitive Proxy Solicitation Materials

On January 13, 2026, Horizon Space Acquisition II Corp. (“HSPT”) filed a definitive proxy statement pursuant to Section 14(a) of the Securities Exchange Act of 1934 (as amended and supplemented, the “Definitive Proxy Statement”) with the Securities and Exchange Commission (the “SEC”) for the solicitation of proxies in connection with an extraordinary general meeting (the “Business Combination Meeting”) of HSPT’s shareholders to be held on February 12, 2026 in connection with the proposed business combination (the “Business Combination”) between HSPT and SL BIO Ltd., a Cayman Islands exempted company limited by shares (“SL Bio”).

In connection with the Business Combination Meeting, HSPT has determined to supplement the Definitive Proxy Statement as follows:

Additional Independent Director Nominees of the Combined Entity Following the Business Combination

In addition to the persons currently disclosed in the Definitive Proxy Statement that are anticipated to become the directors and executive officers of SL Science Holding Limited, a Cayman Islands exempted company limited by shares and the combined entity following the Business Combination (“PubCo”), the following persons will be added as independent nominees of PubCo following the Business Combination:

Joseph Levinson. Mr. Levinson has over 25 years of experience managing cross-border issues for U.S.-listed foreign companies, as well as experience in accounting. From January 2025 to July 2025, Mr. Levinson served as an independent director of Robo.ai Inc., formerly known as NWTN Inc. (Nasdaq: AIIO), a company in the electric vehicle industry. From May 2020 to September 2021, he served as an independent director of China Liberal Education Holdings Ltd. (Nasdaq: CLEU), an educational service provider. Mr. Levinson worked for firms such as KPMG and Deloitte & Touche early in his career. Mr. Levinson received a bachelor’s degree from the University at Buffalo with a double major in finance and accounting, graduating summa cum laude, and he holds a United States Certified Public Accountant license for more than 25 years. He is qualified to serve as a director due to his accounting and public company experience.

Qian (Hebe) Xu. Ms. Xu has served as HSPT’s independent director since November 2024.  She has more than 15 years’ experience in the financial markets as an investment banker, specializing in US-China cross border transactions. Ms. Xu also serves as an Independent Director of Hongli Group Inc. (Nasdaq: HLP), a position held since 2023. Since October 2018, Ms. Xu has served as the founder of HB International Consulting LLC, a firm providing business consulting and financial advisory services. From November 2008 to October 2018, Ms. Xu worked at TriPoint Global Equities LLC, an investment banking firm, as an Analyst (November 2008 to April 2013), as Vice President of investment banking (from April 2013 to May 2017) and the Senior Vice President (from May 2017 to October 2018), leading effort of the US-China cross border investment, mergers & acquisitions, and initial public offerings. Ms. Xu received her Bachelor’s degree in Telecommunication Engineering from Sun Yat-Sen (Zhongshan) University in 2004 and a Master’s degree in Economics from New York University in 2009.

Neither Joseph Levinson nor Qian (Hebe) Xu will serve as a member of PubCo’s board committees.

Accordingly, the persons that are anticipated to become the directors and executive officers of PubCo following the Business Combination are updated and set forth as follows:

Name		Age			Position
William Wang Ching-Dong			54		Chief Executive Officer, Director, and Chairman of Board
Ray Leung			44		Chief Financial Officer
Johnson Lau			52		Vice President of Finance
Ethan Shen, Ph.D.			48		Chief Technology Officer and Director
Kwo-Liang Chen			65		Independent Director Nominee
Mingche Liu, M.D., Ph.D.			52		Independent Director Nominee
John C. General			63		Independent Director Nominee
Joseph Levinson			49		Independent Director Nominee
Qian (Hebe) Xu			43		Independent Director Nominee

As already disclosed in the Definitive Proxy Statement, following the closing of the Business Combination, PubCo expects its executive compensation program to reflect SL Bio’s compensation policies and philosophies, as they may be modified and updated from time to time. Following the closing of the Business Combination, PubCo expects that decisions with respect to the compensation of its executive officers, including the named executive officers, will be made by the compensation committee of PubCo’s board of directors. PubCo’s non-executive independent directors will be entitled to compensations commensurate with their respective duties and experience, including annual or monthly cash retainer, reimbursement of reasonable expenses incurred in relation to the performance of their duties, and, with respect to certain independent directors, equity-based awards pursuant to an equity compensation plan to be adopted following the consummation of the Business Combination.

1

Updated Beneficial Ownership of PubCo Ordinary Shares Immediately Following the Consummation of the Business Combination

As a result of the newly added independent director nominees, the beneficial ownership table disclosed in the section titled “SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT” of the Definitive Proxy Statement regarding the expected beneficial ownership of PubCo Ordinary Shares immediately following the consummation of the Business Combination is updated as follows (assuming there would be 566,591,350 PubCo Ordinary Shares issued and outstanding immediately following the consummation of the Business Combination in the “no redemption” scenario, and 559,956,923 PubCo Ordinary Shares issued and outstanding immediately following the consummation of the Business Combination in the “maximum redemption” scenario):

		Ordinary Shares Beneficially Owned Immediately After Closing of the Business Combination
						Assuming No Redemption				Assuming Maximum Redemption
		Number of PubCo Ordinary Shares				% of PubCo Voting Power				% of PubCo Voting Power
Directors Nominees and Executive Officers(1)
William Wang(3)			333,832,129				58.9	%			59.6	%
Ray Leung			—				—				—
Johnson Lau			—				—				—
Ethan Shen, Ph.D.			—				—				—
Kwo-Liang Chen			—				—				—
Mingche Liu, M.D., Ph.D.			—				—				—
John C. General			—				—				—
Joseph Levinson			—				—				—
Qian (Hebe) Xu (2)			20,000				*				*
All Director Nominees and Executive Officers as a Group			333,852,129				58.9	%			59.6	%
5.0% Shareholders
SL Link Holding Ltd.(3)			333,832,129				58.9	%			59.6	%

Notes:

* Representing less than 1%.

(1) Unless otherwise noted, the business address of each of the following entities or individuals is c/o SL Science Holding Limited, 11^th Floor, No. 479 Chongyang Road, Nangang District, Taipei, Taiwan R.O.C. 115010.

(2) Converted from 20,000 founder shares of HSPT held by Qian (Hebe) Xu.

(3) Following the consummation of the Business Combination, Mr. Wang’s equity interest in the PubCo will be beneficially owned through (i) SL Link Holding Ltd., a company incorporated in the Cayman Islands which is owned equally by Mr. Wang and his spouse and (ii) SL Link Co., Ltd., a company incorporated in Taiwan and controlled by Mr. Wang. On January 5, 2026, SL Link Co., Ltd. and an individual shareholder of SL Bio entered into a securities transfer agreement, pursuant to which the individual shareholder sold 30,000 ordinary shares of par value $0.1 each of SL Bio to SL Link Co., Ltd. at a purchase price of US$66.67 per share. Upon consummation of the Business Combination, Mr. Wang will be the beneficial owner of 329,286,823 PubCo Ordinary Shares through SL Link Holding Ltd. and 4,545,306 PubCo Ordinary Shares through SL Link Co., Ltd.

2

No Change to Meeting Schedule

There is no change to the meeting time, the redemption deadline, the location, the record date, the purpose or any of the proposals to be acted upon at the Business Combination Meeting. The meeting time of the Business Combination Meeting remains at 9:00 a.m. Eastern Time, February 12, 2026, and the redemption deadline in connection with the Business Combination Meeting remains at 5:00 p.m. Eastern Time, February 10, 2026. The physical location of the Business Combination Meeting remains at the offices of Robinson & Cole LLP, 666 Third Avenue, 20th Floor, New York, NY 10017, and virtually via teleconference using the dial-in information: +1 813-308-9980 (Access Code: 173547). The record date for determining the Company’s shareholders entitled to receive notice of and to vote at the Business Combination Meeting remains the close of business on December 29, 2025 (the “Record Date”). Shareholders as of the Record Date can vote, even if they have subsequently sold their shares. Shareholders who have previously submitted their proxies or otherwise voted and who do not want to change their vote need not take any action. Shareholders who have not yet done so are encouraged to vote as soon as possible.

If you have questions regarding the certification of your position or delivery of your shares, please contact:

VStock Transfer, LLC
18 Lafayette Place, Woodmere,
New York 11598
Email: action@vstocktransfer.com
Attn: Action Team

HSPT’s shareholders who have questions regarding the Business Combination Meeting or the impact on the votes casted, or would like to request documents may contact HSPT’s proxy solicitor, Advantage Proxy, Inc., at (877) 870-8565, or banks and brokers can call (206) 870-8565, or by email at ksmith@advantageproxy.com.

Forward-Looking Statements

This Current Report on Form 8-K includes forward looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts and may be accompanied by words that convey projected future events or outcomes, such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “predict,” “seek,” “target,” “aim,” “plan,” “project,” “forecast,” “should,” “would,” or variations of such words or by expressions of similar meaning. Such forward-looking statements, including statements regarding the advantages and expected growth of the combined company, the cash position of the combined company following the closing, the ability of HSPT and SL Bio to consummate the proposed Business Combination and the timing of such consummation, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in the section entitled “Risk Factors” in HSPT’s Annual Report on Form 10-K filed with the SEC on March 27, 2025 (the “Form 10-K”), HSPT’s final prospectus dated November 14, 2024 filed with the SEC (the “Final Prospectus”) related to its initial public offering, the Definitive Proxy Statement dated January 13, 2026 filed with the SEC and the amendments and supplements thereto in connection with the Business Combination, and in other documents filed by HSPT with the SEC from time to time. Important factors that could cause the combined company’s actual results or outcomes to differ materially from those discussed in the forward-looking statements include: SL Bio’s or the combined company’s limited operating history; the ability of SL Bio or the combined company to identify and integrate acquisitions; general economic and market conditions impacting demand for the products of SL Bio or the combined company; the inability to complete the proposed Business Combination; the inability to recognize the anticipated benefits of the proposed Business Combination, which may be affected by, among other things, the amount of cash available following any redemptions by HSPT’s shareholders; the ability to meet stock exchange’s listing standards following the consummation of the proposed Business Combination; costs related to the proposed Business Combination; and such other risks and uncertainties as are discussed in the Form 10-K, the Final Prospectus and Definitive Proxy Statement and the amendments and supplements thereto. Other factors include the possibility that the proposed Business Combination do not close, including due to the failure to receive required security holder approvals, or the failure of other closing conditions.

SL Bio, PubCo and HSPT each expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the expectations of SL Bio, PubCo or HSPT with respect thereto or any change in events, conditions or circumstances on which any statement is based, except as required by law.

4

Additional Information about the Transaction and Where to Find It

In connection with the proposed Business Combination, PubCo has filed with the SEC the registration statement on Form F-4 (the “Registration Statement”), which includes the Definitive Proxy Statement containing information about the proposed Business Combination. The Registration Statement was declared effective on January 13, 2026, and the Definitive Proxy Statement is first being mailed to HSPT’s shareholders as of the Record Date established for voting on the proposed Business Combination on or about January 13, 2026.

INVESTORS AND SECURITY HOLDERS ARE ADVISED TO READ THE REGISTRATION STATEMENT, DEFINITIVE PROXY STATEMENT, AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE BUSINESS COMBINATION AND THE PARTIES TO THE BUSINESS COMBINATION. Investors and security holders will be able to obtain copies of these documents (if and when available) and other documents filed with the SEC free of charge at www.sec.gov. Shareholders of HSPT will also be able to obtain copies of the Definitive Proxy Statement without charge, at the SEC’s website at www.sec.gov.

Participants in the Solicitation

PubCo, SL Bio, HSPT and their respective directors and executive officers and other persons may be deemed to be participants in the solicitation of proxies from HSPT’s shareholders with respect to the proposed Business Combination. Information regarding HSPT’s directors and executive officers is available in HSPT’s filings with the SEC. Additional information regarding the persons who may, under the rules of the SEC, be deemed to be participants in the proxy solicitation relating to the proposed Business Combination and a description of their direct and indirect interests, by security holdings or otherwise are contained in the Definitive Proxy Statement.

No Offer or Solicitation

This Current Report on Form 8-K does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.		Description
10.1		Form of Director Offer Letter.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

5

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Horizon Space Acquisition II Corp.
	By:	/s/ Mingyu (Michael) Li
	Name:	Mingyu (Michael) Li
	Title:	Chief Executive Officer

Date: February 6, 2026

6

FAQ

What did Horizon Space Acquisition II Corp. (HSPT) update in this filing?

The filing updates proxy materials for the proposed business combination with SL BIO Ltd., adding two independent director nominees for PubCo and revising the expected post-closing ownership table. It also confirms that the Business Combination Meeting schedule and key deadlines remain unchanged.

Who are the new independent director nominees for PubCo after the HSPT–SL Bio merger?

The filing adds Joseph Levinson and Qian (Hebe) Xu as independent director nominees for PubCo. Levinson brings accounting and U.S.-listed company experience, while Xu contributes over 15 years in cross-border investment banking and currently serves as an HSPT independent director.

What is the expected ownership of PubCo shares after the Horizon Space–SL Bio business combination?

Assuming no redemptions, PubCo expects 566,591,350 ordinary shares outstanding, with William Wang beneficially owning 333,832,129 shares, representing 58.9% voting power. In the maximum redemption scenario, 559,956,923 shares are expected, and his voting power would be 59.6%.

When is the Business Combination Meeting for Horizon Space Acquisition II Corp. shareholders?

The Business Combination Meeting is scheduled for 9:00 a.m. Eastern Time on February 12, 2026. It will be held physically at Robinson & Cole LLP in New York and virtually via teleconference, with dial-in access information provided in the disclosure.

What is the redemption deadline for HSPT shareholders regarding the SL Bio business combination?

The redemption deadline remains 5:00 p.m. Eastern Time on February 10, 2026. Shareholders who wish to redeem must meet this cutoff while shareholders of record as of December 29, 2025 retain the right to vote at the Business Combination Meeting.

Does this HSPT filing change the proposals or purpose of the Business Combination Meeting?

No, the purpose, proposals, meeting time, location, record date, and redemption deadline are unchanged. The update is focused on adding independent director nominees, revising expected post-closing ownership, and reminding shareholders how to access proxy materials and assistance.

Where can Horizon Space Acquisition II Corp. investors find full details on the SL Bio transaction?

Investors can review the Form F-4 Registration Statement and Definitive Proxy Statement filed with the SEC, which include detailed information about the proposed business combination. These documents are available free of charge at the SEC’s website, www.sec.gov.